Equities analysts expect that ChemoCentryx Inc (NASDAQ:CCXI) will post earnings per share (EPS) of ($0.21) for the current quarter, according to Zacks. Six analysts have made estimates for ChemoCentryx’s earnings, with estimates ranging from ($0.27) to ($0.13). ChemoCentryx posted earnings per share of ($0.14) in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The firm is scheduled to issue its next earnings results on Thursday, August 8th.
On average, analysts expect that ChemoCentryx will report full-year earnings of ($0.92) per share for the current financial year, with EPS estimates ranging from ($1.28) to ($0.70). For the next year, analysts expect that the business will post earnings of ($1.07) per share, with EPS estimates ranging from ($1.50) to ($0.56). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The company had revenue of $8.33 million during the quarter, compared to the consensus estimate of $11.37 million. ChemoCentryx had a negative return on equity of 111.15% and a negative net margin of 97.22%.
CCXI has been the subject of a number of recent analyst reports. ValuEngine downgraded ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Monday, May 20th. Zacks Investment Research upgraded ChemoCentryx from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a report on Wednesday, May 15th. BidaskClub cut ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Wednesday. Raymond James reduced their price target on ChemoCentryx from $24.00 to $17.00 and set a “strong-buy” rating on the stock in a research note on Thursday, June 6th. Finally, B. Riley raised ChemoCentryx from a “neutral” rating to a “buy” rating and upped their price target for the stock from $12.50 to $22.00 in a research note on Wednesday, March 27th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $17.71.
In other news, CEO Thomas J. Schall sold 5,755 shares of the stock in a transaction on Friday, March 29th. The stock was sold at an average price of $14.00, for a total value of $80,570.00. Following the sale, the chief executive officer now directly owns 2,234,610 shares of the company’s stock, valued at $31,284,540. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Geoffrey M. Parker sold 12,815 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $12.00, for a total value of $153,780.00. Following the completion of the sale, the director now directly owns 85,014 shares in the company, valued at $1,020,168. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 246,570 shares of company stock worth $3,313,980. 12.20% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kore Private Wealth LLC purchased a new stake in shares of ChemoCentryx in the first quarter worth $28,000. BNP Paribas Arbitrage SA grew its stake in shares of ChemoCentryx by 46,860.0% in the first quarter. BNP Paribas Arbitrage SA now owns 4,696 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 4,686 shares during the last quarter. Meeder Asset Management Inc. grew its stake in shares of ChemoCentryx by 103.5% in the first quarter. Meeder Asset Management Inc. now owns 6,176 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,141 shares during the last quarter. Citigroup Inc. grew its stake in shares of ChemoCentryx by 67.7% in the first quarter. Citigroup Inc. now owns 6,829 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 2,756 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its stake in shares of ChemoCentryx by 369.8% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,804 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 6,930 shares during the last quarter. 58.14% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ChemoCentryx stock traded down $0.34 during midday trading on Friday, reaching $8.34. 228,609 shares of the company’s stock traded hands, compared to its average volume of 538,028. The company has a quick ratio of 3.43, a current ratio of 3.43 and a debt-to-equity ratio of 0.24. The company has a market cap of $484.12 million, a PE ratio of -10.97 and a beta of 1.37. ChemoCentryx has a 12 month low of $8.06 and a 12 month high of $14.98.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Featured Article: How do candlesticks reflect price movement?
Get a free copy of the Zacks research report on ChemoCentryx (CCXI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.